Therapeutic Spectrum

Full Strategic Pipeline

ACA Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary Upstream–Midstream–Downstream (UMD) Framework to systematically address disease biology across multiple pathways. Our platform is designed to efficiently generate and prioritize therapeutic programs across oncology, neurology, metabolic, and rare diseases. Our pipeline reflects a prioritized development strategy, with a lead clinical program and a broad portfolio of indications supported by translational research and prepared for efficient advancement toward IND submission.

Learn More
Our Pipeline Photo

I. Lead Clinical Programs

  • ACA-001: Pancreatic Cancer — Phase I IND Cleared (Trial Ready)
  • ACA-002: Type 2 Diabetes (T2DM) & Beta-Cell Restoration — Phase I IND Submission Planned
  • ACA-003: Benign Prostatic Hyperplasia (BPH) with Chronic Non-bacterial Prostatitis (CNP) —Phase I IND Submission Planned
  • ACA-004: Alzheimer’s Disease (AD) — Restoring Cognitive Pathways — Phase I IND Submission Planned

II. Core Pipeline Programs (IND-Ready Potential)

Oncology & Rare Cancers

  • ACA-005: Lung Cancer (NSCLC/SCLC)
  • ACA-006: Neuroendocrine Tumors (NEC)
  • ACA-007: Colorectal Cancer
  • ACA-008: Prostate Cancer
  • ACA-009: Gynecologic & Fallopian Tube Cancer (FTC)
  • ACA-010: Squamous Cell Carcinoma
  • ACA-011: Renal Cell Carcinoma
  • ACA-012: Bladder Cancer
  • ACA-013: Gastric Cancer / GIST
  • ACA-014: Brain Tumors & Glioma
  • ACA-015: Melanoma
  • ACA-016: Universal Lymphoma Subsets
  • ACA-017: Myelodysplastic Syndrome (MDS)
  • ACA-018: Acute Myeloid Leukemia (AML)
  • ACA-019: Appendiceal Cancer
  • ACA-020: Cholangiocarcinoma (iCCA)
  • ACA-021: Chronic Lymphocytic Leukemia (CLL)
  • ACA-022: Ewing Sarcoma
  • ACA-023: Follicular Lymphoma
  • ACA-024: Hepatocellular Carcinoma (HCC / FL-HCC)
  • ACA-025: Hodgkin Lymphoma
  • ACA-026: Multiple Myeloma
  • ACA-027: Small Intestine Cancer (SIC)
  • ACA-028: Breast Cancer (Triple Negative / General)
  • ACA-029: Immune-Driven NF-κB/AKT Dysregulation Subtype Disorders

Neurology & Neuro-Psychiatry

  • ACA-030: ADHD (Attention Deficit Hyperactivity Disorder) — Systemic Neuromodulation
  • ACA-031: Autism Spectrum Disorder (ASD) — Targeting Immune-Brain Axis Dysregulation
  • ACA-032: Myasthenia Gravis (MG) & Thymoma — Neuromuscular Junction Restoration
  • ACA-033: Alzheimer’s Disease (AD) — Restoring Cognitive Pathways
  • ACA-034: Parkinson’s Disease (PD) — Resolving Neuro-Inflammation

Ophthalmology & Regenerative Care

  • ACA-035: Macular Degeneration — Retinal Micro-environment Restoration
  • ACA-036: Optic Nerve Regeneration & Advanced Fundus Diseases

Systemic Immune & Metabolic Pillar

  • ACA-037: Hyperlipidemia / Dyslipidemia — Upstream Metabolic Reset for Lipid Homeostasis & Cardiovascular Protection
  • ACA-038: Obesity — Upstream Metabolic Reset for Weight Homeostasis & Metabolic Comorbidity Resolution
  • ACA-039: Restless Leg Syndrome (RLS)
  • ACA-040: Polycythemia Vera
  • ACA-041: Salivary Gland Adenocarcinoma
  • ACA-042: Soft-Tissue Sarcomas
  • ACA-043: Psoriasis
  • ACA-044: Vocal Cord Leukoplakia
  • ACA-045: Lyme Disease (Chronic/Refractory)
  • ACA-046: Osteoarthritis (Chronic Joint Inflammation)
  • ACA-047: Chronic Kidney Disease (CKD)

III. Rare Diseases / Orphan Indications

Platform leverages upstream reset to enable low-dose intermittent downstream therapy, reducing toxicity and cost. Many carry Orphan Drug Initiative potential.

  • [ACAR – 001]: Prader-Willi Syndrome
  • [ACAR – 002]: Leber Hereditary Optic Neuropathy (LHON)
  • [ACAR – 003]: Non-Dystrophic Myotonia
  • [ACAR – 004]: Pediatric Glioma

Platform Advantage

The UMD Framework enables a systems-level approach by targeting upstream drivers, midstream signaling pathways, and downstream disease manifestations. This integrated strategy supports the efficient generation of multiple therapeutic programs and allows flexible prioritization for clinical development and partnership opportunities.

Scroll to Top